MTAP免疫组化在胰腺导管腺癌FNA及小活检中的诊断效用
本研究评估了甲基硫代腺苷磷酸化酶(MTAP)免疫组化在超声内镜引导下细针穿刺(EUS-FNA)细胞块或核心活检诊断胰腺导管腺癌(PDAC)中的价值。在136例靶向实性胰腺肿块的标本中,80例PDAC有23例(29%)显示MTAP表达完全缺失,且所有形态学不确定但MTAP缺失的病例经切除或额外采样均证实为PDAC,无良性样本显示缺失。在13例有临床二代测序数据的样本中,4例MTAP缺失者均检出CDKN2A拷贝数丢失。结论认为MTAP免疫组化可支持小活检样本中PDAC的诊断。
要点
- MTAP表达完全缺失见于29%(23/80)的PDAC小活检标本。
- 形态学不确定但MTAP缺失的病例均经切除或额外采样证实为PDAC。
- 无良性样本(n=13)显示MTAP缺失,支持其特异性。
核心结论
- MTAP免疫组化表达缺失约见于30%的PDAC小活检标本,可支持PDAC诊断。
研究设计与样本
- 回顾性分析136例EUS-FNA细胞块或核心活检靶向实性胰腺肿块的病例,行MTAP免疫组化并与部分病例的临床二代测序结果相关性分析。
主要发现
- 80例PDAC中23例(29%)显示MTAP表达完全缺失。
- 21例可疑病例中4例、22例不典型病例中4例显示MTAP缺失。
- 所有形态学不确定且MTAP缺失的病例经切除或额外采样证实为PDAC。
- 13例良性样本均无MTAP缺失。
- 13例有二代测序数据的样本中,4例MTAP缺失者均检出CDKN2A拷贝数丢失。
临床怎么用
- 在EUS-FNA细胞块或小活检标本中,MTAP免疫组化缺失可辅助支持PDAC的诊断,尤其适用于形态学不确定的病例。
局限性
- MTAP缺失仅见于约30%的PDAC,敏感性有限。
- 二代测序数据仅来自13例样本,样本量小。
- 良性样本量较少(n=13)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accurate diagnosis of pancreatic lesions by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) or fine-needle biopsy can be challenging. Although surrogate immunohistochemical markers for genetic alterations associated with pancreatic ductal adenocarcinoma (PDAC) have been identified, they have modest sensitivity. Biallelic loss of CDKN2A occurs in up to 46% of PDACs, and methylthioadenosine phosphorylase (MTAP) immunohistochemistry (IHC) has been identified as a reliable surrogate marker for this alteration. The current study evaluates the utility of MTAP IHC for the diagnosis of PDAC. METHODS: In total, 136 cases of EUS-FNA cell block or core biopsy targeting solid pancreatic masses were identified. MTAP IHC was performed and evaluated for complete loss of expression in neoplastic cells. These results were correlated with available clinical next-generation sequencing that was performed on a subset of cases. RESULTS: Complete loss of MTAP expression was identified in 23 of 80 (29%) PDACs. A subset of cases classified as suspicious (4 of 21) and atypical (4 of 22) showed MTAP loss. All morphologically indeterminate cases with MTAP loss were confirmed as PDAC on resection/additional sampling. No benign samples (n = 13) showed loss of MTAP. In samples that had available clinical next-generation sequencing data (n = 13), copy number loss of CDKN2A was detected in all cases that had loss of MTAP expression (n = 4). CONCLUSIONS: Loss of MTAP was identified in approximately 30% of PDAC small biopsy specimens. As loss of MTAP expression is not expected in nonneoplastic cells, and these findings suggest that MTAP IHC can support a diagnosis of PDAC in small biopsy samples.
引用
- Yu S, Doyle LA, Hornick JL, et al. The diagnostic utility of methylthioadenosine phosphorylase immunohistochemistry for pancreatic ductal adenocarcinoma in FNA and small biopsy specimens. Cancer Cytopathol. 2023. PMID: 38054349. doi:10.1002/cncy.22777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。